Member Info for roses

Indeed, seems way too low for what’s coming next !

New valuation from trinity delta 33p per share (£270m)

Well if we can’t work it out, then listen to the people who do know !

Honorary Prof Rod Dawson, Managing Director of the University of Cape Town Lung Institute, commented:

"We are delighted to report the positive immune response data from the COVIDTY trial. 66 participants were immunised with SCOV1, targeting the original A lineage of SARS-CoV-2 and/or SCOV2, targeting the Beta variant of concern. The results from the trial were highly encouraging, inducing neutralising antibody and T cell responses with no safety concerns." '

Well firstly, the spread isn’t 11%

The spread is 2.67% and even smaller on live prices

Well done Scancell.

“As previously disclosed “

Now where did we hear that ?

Mattrempit what is Marcus’ video ?

‘Pot of gold’

Pog is an acronym for one of the sclp threads on the other side

Very interesting !

“As previously disclosed”

They are doing what they already stated previously !

M&A. Jean-Michel was Vice President for North America Oncology at Eli Lilly, with responsibility for commercialisation of the company's oncology portfolio . Preceding this US-based position, he was Vice President and Managing Director of the Eli Lilly's European Northern Hub, where he was Chair of the Eli Lilly UK Board and a member of Lilly European Executive Committee. Prior to this Jean-Michel served as VP and Chief Marketing Officer at GE Healthcare's Global Headquarters.

Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the board of Kymab until their acquisition by Sanofi. He was also a member of the Immunocore board prior to the company's Nasdaq listing.

New chairman,

Very interesting background.

Always happens before a big move in the share price.

I’m betting that he will say he is unable to.

“It’s Still Worth Funding a Better Covid Vaccine”

https://www.bloomberg.com/opinion/articles/2023-01-29/a-better-covid-vaccine-could-prevent-transmission-and-long-covid?srnd=premium-europe&leadSource=uverify%20wall

I also have done an extensive search and am also a subscriber to Bloomberg premium content and can confirm there is not and has not been any mention of an investor roadshow, it does seem someone with alterior motives has made it up.

Not only that but shares magazine have got their figures all wrong.

https://www.bloomberg.com/news/articles/2023-01-25/uk-covid-panel-tells-government-to-plan-for-autumn-booster-jabs?srnd=premium-europe

$6 million dollar up front payment with hopefully another 650 million payment.

Looking good

Indeed, re. Covidity, they said “ as previously disclosed”